Subscribe to RSS - average sales price

average sales price

In brief: Two senators back bid bill, groups seek vent changes

 - 
04/08/2016

WASHINGTON – HME stakeholders have added two co-sponsors to a bill in the Senate that would delay a second round of Medicare reimbursement cuts slated for July 1.

ASP: Budesonide takes a dive

 - 
04/06/2016

BALTIMORE – Second quarter payments for respiratory drugs are up in most cases, with the exception of Budesonide (J7626), which decreased sharply, down nearly 73 cents per dose.

NHIA pushes back on ASP

 - 
07/27/2015

WASHINGTON – The House of Representatives on June 17 passed a bill that included a provision that would switch payment for Part B home infusion drugs to an average sales price model—a model that is unsustainable, say infusion stakeholders.

In brief: Judge favors Lincare in whistleblower lawsuit, neb-med payments are up and down

 - 
07/17/2015

MIAMI – A federal judge has ruled that two former Lincare employees failed to prove the provider violated Medicare telemarketing rules.

ASP: Up for brand name neb-meds

 - 
07/17/2015

BALTIMORE – Third-quarter payments for respiratory drugs are up and down. Brand name drugs Brovana (J7605) and Perforomist (J7606) were up 16 cents and nearly 44 cents to $7.20 and $8.48 per dose, respectively.

ASP: Perforomist sees healthy jump

 - 
10/03/2014

BALTIMORE – Fourth-quarter payments for respiratory drugs is up nearly across the board. Brand name drug Perforomist (J7606) saw the biggest jump, up nearly 90 cents, to $7.46 per dose according to the latest average sales price (ASP) figures.

OIG to CMS: Get all drug manufacturers to submit ASPs

 - 
07/23/2014

CMS lacks complete average sales price (ASP) data for certain drugs, hindering its ability to ensure that payment amounts are accurate and reflective of manufacturer sales prices, according to a new report from the Office of Inspector General (OIG).

ASP: Brovana sees another increase

 - 
06/19/2014

BALTIMORE – Payment increased for brand-name drug Brovana (J7605) in the third quarter of 2014 to $6.39 per dose, up 25 cents from the previous quarter, according to average sales price (ASP) figures released June 17.

ASP: Brand-name drugs see increase

 - 
03/13/2014

BALTIMORE – Two nebulizer medications will see payment increases for the second quarter of 2014.

ASP: Budesonide reverses course

 - 
12/11/2013

BALTIMORE – When it comes to nebulizer medication pricing, one quarter you’re up; another quarter you’re down.

Pages